HOXA13 is a potential GBM diagnostic marker and promotes glioma invasion by activating the Wnt and TGF-β pathways

Ran Duan; Lei Han; Qixue Wang; Jianwei Wei; Luyue Chen; Jianning Zhang; Chunsheng Kang; Lei Wang

doi:10.18632/oncotarget.4813

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

HOXA13 is a potential GBM diagnostic marker and promotes glioma invasion by activating the Wnt and TGF-β pathways

Ran Duan, Lei Han, Qixue Wang, Jianwei Wei, Luyue Chen, Jianning Zhang, Chunsheng Kang and Lei Wang _

PDF | HTML | How to cite

Oncotarget. 2015; 6:27778-27793. https://doi.org/10.18632/oncotarget.4813

Metrics: PDF 2600 views | HTML 2919 views | ?

Abstract

Ran Duan1,5, Lei Han2,3,4,5, Qixue Wang2,3,4,5, Jianwei Wei2,3,4,5, Luyue Chen2,3,4,5, Jianning Zhang3,4,5, Chunsheng Kang2,3,4,5, Lei Wang1,5,6

1Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China

2Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin, China

3Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China

4Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government, Tianjin, China

5Chinese Glioma Cooperative Group (CGCG), Beijing, China

6China National Clinical Research Center for Neurological Diseases, Beijing, China

Correspondence to:

Lei Wang, e-mail: [email protected]

Chunsheng Kang, e-mail: [email protected]

Keywords: Homeobox (HOX) gene, HOXA13, glioma, SMAD, epithelial-to-mesenchymal transition (EMT)

Received: March 21, 2015 Accepted: July 20, 2015 Published: July 31, 2015

ABSTRACT

Homeobox (HOX) genes, including HOXA13, are involved in human cancer. We found that HOXA13 expression was associated with glioma grade and prognosis. Bioinformatics analysis revealed that most of the HOXA13-associated genes were enriched in cancer-related signaling pathways and mainly involved in the regulation of transcription. We transfected four glioma cell lines with Lenti-si HOXA13. HOXA13 increased cell proliferation and invasion and inhibited apoptosis. HOXA13 decreased β-catenin, phospho-SMAD2, and phospho-SMAD3 in the nucleus and increased phospho-β-catenin in the cytoplasm. Furthermore, downregulation of HOXA13 in orthotopic tumors decreased tumor growth. We suggest that HOXA13 promotes glioma progression in part via Wnt- and TGF-β-induced EMT and is a potential diagnostic biomarker for glioblastoma and an independent prognostic factor in high-grade glioma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4813

Publication Alerts

Research Papers:

HOXA13 is a potential GBM diagnostic marker and promotes glioma invasion by activating the Wnt and TGF-β pathways

Abstract